EGFR and neoplasm: Consistent with this study, another clinical trial observed a response with lapatinib treatment with prolonged tumor stabilization of more than 6 months in recurrent or metastatic salivary gland carcinoma patients, suggesting that targeted therapy with anti-EGFR therapeutics may improve the clinical outcomes of patients suffering from malignant salivary gland tumors [199].